BC
PNT

Bridgefront Capital’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Bridgefront Capital’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,829
Closed -$93.5K – 627
2022
Q4 		$93.5K Buy
+12,829
New +$95.2K 0.07% 339

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridgefront Capital's PNT Position: Q1 2023 in Review

Bridgefront Capital sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q1 2023, closing a stake of 12,829 shares — an estimated $93.5K sold.

Bridgefront Capital first reported a position in PNT in Q4 2022 and held it in 1 quarter. The position peaked at $93.5K in Q4 2022. 115 funds tracked by Wall St. Rank hold PNT as of Q1 2023.

  • Bridgefront Capital reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bridgefront Capital sold 12,829 POINT Biopharma Global Inc. Common Stock shares in Q1 2023, an estimated $93.5K.
  • Bridgefront Capital first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Bridgefront Capital's POINT Biopharma Global Inc. Common Stock position peaked at $93.5K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q1 2023.

Based on Bridgefront Capital's 13F filing for Q1 2023, filed 15 May 2023.